Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.

BMC Cancer · 2016 · PMC4872363 · PMID 27194176

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Ultimately, the nCRT in this trial’s population provided a highly significant 34 % reduction of the risk of death, as well as a significant 42 % reduction of the risk of relapse [ 4 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.